Table 2 Potential application of circRNAs in HCC
From: Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer
circRNA | Stage | Functional mechanism | Potential application | References |
|---|---|---|---|---|
cSMARCA5 | Prediction | cSMARCA5 could sponge miR-17-3p and miR-181b-5p to upregulate TIMP3 | 1. A potential diagnostic biomarker in HCC (AUC values of 0.938 and 0.862) 2. A potential prognostic biomarker in HCC | [36] |
circPABPC1 | Pre-clinic | AR/ADAR1/CircPABPC1 axis | Potential therapeutic value for HCC through reactivation of this circular RNA | [30] |
circPABPC1 | Pre-clinic | circPABPC1 physically links ITGB1 to the 26S proteasome for ubiquitination-independent degradation | Potential therapeutic value for HCC treatment (technically possible with RNA-delivering methods) | [60] |
circMAT2B | Pre-clinic | circMAT2B/miR-338-3p/PKM2 axis | 1. A potential therapeutic target for HCC 2. A potential prognostic biomarker in HCC | [44] |
circCDYL | Pre-clinic | circCDYL/miR-892a/HDGF circCDYL/miR-328-3p/HIF1AN | 1. Promising biomarkers (combined with HDGF and HIF1AN) for surveillance in early stages of HCC (AUC values of 0.73, while the AUC of AFP was low at 0.59) 2. Potential therapeutic value in early treatment of HCC | [39] |
circSETD3 | Pre-clinic | circSETD3/miR-421/MAPK14 axis | 1. A prognostic biomarker in patients with HCC who have received curative liver resection 2. A potential therapeutic target for HCC | [57] |
circMTO1 | Pre-clinic | circMTO1/miR-9/p21 axis | 1. A prognostic biomarker for HCC patients 2. A potential target in HCC treatment | [56] |
circFBXO11 | Pre-clinic | circFBXO11/miR-605/FOXO3/ ABCB1 axis | 1. A potential diagnostic biomarker in HCC 2. A potential therapeutic target for overcoming oxaliplatin resistance in HCC | [121] |
circSORE | Pre-clinic | circSORE binds to YBX1 protein to prevent its PRP19-mediated degradation | 1. A promising biomarker (exosome-carrying-circRNA-SORE) for early detection 2. Potential therapeutic value of circSORE siRNA for overcoming sorafenib resistance 3. Sorafenib resistance testing | [53] |
circUHRF1 | Pre-clinic | circUHRF1/miR-449c-5p/TIM-3 axis | 1. Exosomal circUHRF1 provides a potential therapeutic value for overcoming anti-PD1 resistance in HCC 2. Anti-PD1 resistance testing | [51] |
circFN1 | Pre-clinic | circFN1/miR-1205/E2F1 axis | 1. The circFN1/miR-1205/E2F1 signaling pathway may provide novel strategies to overcome sorafenib resistance in HCC 2. Sorafenib resistance testing | [101] |